DESIGNING OFA PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN INHIBITOR, IN ADULTS WITH PRIMARY SJOGREN'S SYNDROME-MedSci.cn

DESIGNING OFA PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN INHIBITOR, IN ADULTS WITH PRIMARY SJOGREN'S SYNDROME

Hubbard, JJ; Campbell, K; Sivils, K; Hoffman, RW; Lo, KH; Leu, JH; Perdomo, AMB; Liva, SG; Zuraw, Q; Stevens, AM; Ling, LE; Karcher, K; Ramchandren, S; Sun, H; Scofield, RH; Seror, R; Wallace, DJ

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023; 29 (): S55

科室
- - 订阅+
  - 更多科室
工具
服务